Our Partners
Advancing Therapeutic Options Around the World
Fortis Partnership
In May 2023, Kyntra Bio entered into an exclusive license with Fortis Therapeutics for FOR46 (FG-3246), a potential first-in-class Phase 2 ADC targeting CD46, a novel epitope on the surface of prostate cancer cells. FG-3246 is being developed for the treatment of mCRPC. Kyntra Bio has initiated a Phase 2 trial in mCRPC, with the potential for additional trials targeting other CD46-expressing cancers. As part of this trial, Kyntra Bio is also studying FG-3180, a PET-based biomarker utilizing a radiolabeled version of the targeting antibody to assess the correlation between expression of CD46 and response to FG-3246.
Astellas Partnership
Kyntra Bio and Astellas have a longstanding strategic partnership focused on the development and commercialization of roxadustat, an oral HIF-PH inhibitor for the treatment of anemia. Established in 2004, the collaboration grants Astellas rights to develop and market roxadustat in Japan, Europe, the Middle East, Russia and the Commonwealth of Independent States, Turkey, South Africa, and select other territories. The partnership has been instrumental in securing regulatory approvals for roxadustat in multiple regions and combines Kyntra Bio’s scientific leadership with Astellas’ commercial and regulatory expertise to expand access to innovative treatments for anemia associated with chronic kidney disease.
Partnering Opportunities
Kyntra Bio has retained the rights to roxadustat in the U.S., Canada, Mexico, and in all markets not held by Astellas Pharma (excluding China and South Korea).